Adjunctive Therapy For Parkinson's Disease Therapeutics
1. Xadago patent expiration
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8278485 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Jun, 2027
(1 year, 4 months from now) | |
| US8076515 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Dec, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8283380 | MDD US | Methods for treatment of parkinson's disease |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2022 |
Drugs and Companies using SAFINAMIDE MESYLATE ingredient
NCE-1 date: 21 March, 2021
Market Authorisation Date: 21 March, 2017
Dosage: TABLET
More Information on Dosage
XADAGO family patents
